Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Izokibep · 2 trials · 2 indications
HiSCR75 was defined as at least a 75% reduction from baseline in the total abscess and inflammatory nodule count, with no increase from baseline in abscess or draining fistula count.
HiSCR75 was defined as at least a 75% reduction from baseline in the total abscess and inflammatory nodule count, with no increase from baseline in abscess or draining fistula count.
Complete Response is defined as Yes/No by visit by meeting at least 1 of the following criteria in at least one eye: 1. Inflammatory, chorioretinal and/or inflammatory retinal vascular lesions - No such active lesions; all prior lesions appear inactive 2. ACC Count - Trace or absent (0.5+ or 0) 3. Vitreous Haze - Trace or absent (0.5+ or 0)
| Arm | Type | Description |
|---|---|---|
| Part A (Open-label) izokibep every week | EXPERIMENTAL | Participants will receive izokibep every week from Day 1 through Week 31 |
| Part B (Double-blind) izokibep every week | EXPERIMENTAL | Participants will receive izokibep every week for 31 weeks. |
| Part B (Double-blind) izokibep every other week | EXPERIMENTAL | Participants will receive izokibep every other week for 30 weeks. |
| Part B (Double-blind) placebo every week | PLACEBO_COMPARATOR | Participants will receive placebo every week up to Week 15, then izokibep from Week 16 to Week 31. |
| Part B (Double-blind) placebo every other week | PLACEBO_COMPARATOR | Participants will receive placebo every other week up to Week 14, then izokibep from Week 16 to Week 30. |
| Izokibep and maintenance corticosteroid dose | EXPERIMENTAL | Izokibep+ Prednisolon/Prednisone |
| Name | Type | Description |
|---|---|---|
| Izokibep | DRUG | Biologic: IL-17A inhibitor Form: Solution for injection Route of administration: Subcutaneous (SC) |
| Placebo to izokibep | DRUG | Form: Solution for injection Route of administration: Subcutaneous (SC) |
| Prednisone/Prednisolone | DRUG | Background Corticosteroid |
Inclusion Criteria: General * Subject has provided signed informed consent including consenting to comply with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. * 18 years to 75 years of age Type of Subject and Disease Characteristics * Diagnosis o...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 5 | PHASE3 | Upadacitinib |
| Incyte Corporation | INCY | 6 | PHASE3 | Povorcitinib |
| Novartis AG Sponsored ADR | NVS | 11 | PHASE3 | Remibrutinib Dose A, Remibrutinib Dose B |
| MoonLake Immunotherapeutics Class A | MLTX | 2 | PHASE3 | Sonelokimab |
| Sanofi SA Sponsored ADR | SNY | 2 | PHASE2 | Brivekimig |
| Pfizer Inc. | PFE | 1 | PHASE2 | Ritlecitinib |
| Merck & Co., Inc. | MRK | 1 | PHASE2 | Tulisokibart |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 1 | PHASE2 | Zasocitinib |
| Zura Bio Limited Class A | ZURA | 1 | PHASE2 | Tibulizumab Dose A, Tibulizumab Dose B |
| Sonoma Pharmaceuticals, Inc. | SNOA | 2 | PHASE1 | SBT777101 |
| Evommune, Inc. | EVMN | 1 | EARLY_PHASE1 | EVO101 |
Izokibep is an investigational drug being studied for the treatment of hidradenitis suppurativa and uveitis. It is currently in Phase 2 clinical development for these conditions. Izokibep is being developed by ACELYRIN, INC. (ticker: SLRN).
Izokibep is being developed by ACELYRIN, INC., a biopharmaceutical company. The company's stock ticker is SLRN. Izokibep is an investigational small molecule being studied for hidradenitis suppurativa and uveitis.
Izokibep is in Phase 2 clinical development. It has completed two Phase 2 trials, one in non-anterior uveitis and one in hidradenitis suppurativa. Izokibep is investigational and has not been approved by regulatory authorities.
Izokibep has completed two Phase 2 clinical trials. NCT04706741 studied Izokibep in non-anterior uveitis with 7 participants in the United States. NCT05355805 studied Izokibep in hidradenitis suppurativa with 205 participants across the United States, Canada, Germany, Hungary, Poland, and Spain.
Izokibep is not FDA approved. It is an investigational drug currently in Phase 2 clinical development for hidradenitis suppurativa and uveitis. The completed trials include a placebo-controlled study in hidradenitis suppurativa and a study in non-anterior uveitis.